Protein Biomarker Firm Astute Medical Completes $40.4M Series C Round | GenomeWeb

NEW YORK (GenomeWeb News) – Protein biomarker diagnostics firm Astute Medical today announced the completion of a Series C financing round that raised $40.4 million.

The funding will go toward the commercialization of Astute's first product and to expand its research, development, and validation of biomarker-based laboratory tests.

The round was led by MPM Capital and new investor Kaiser Permanente Ventures. Other participants included De Novo Ventures, Delphi Ventures, Domain Associates, and Johnson & Johnson Development.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.